Polymorphisms toll like receptor genes predicts clinical outcomes of colorectal cancer patients
AssigneeUniversity of Southern California
InventorHeinz-Josef Lenz
Life of this patent
Estimating the term…
Abstract
Methods are provided for identifying the clinical outcome of cancer patients following a therapy comprising cetuximab or irinotecan plus bevacizumab. The methods entail screening a cell or tissue sample isolated from the patient for an rs3853839 or rs5743618 polymorphism. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating the patient.
Claims28
An in vitro method of detecting a polymorphism in a cancer patient or a patient suspected of having cancer, the method comprising screening a biological sample from the patient to detect the genotype of (G/G) for rs3853839.
-12. (canceled)
-26. (canceled)
An in vitro method of detecting a polymorphism in a cancer patient or a patient suspected of having cancer, the method comprising screening a biological sample from the patient to detect the genotype of (G/T) or (G/G) for rs5743618.
-39. (canceled)
-52. (canceled)
Dependencies are inferred from the claim text.